English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAn online pharmacy offering standardized, transparent pricing can reduce out-of-pocket costs for patients taking common medications prescribed by urologists, suggests a study in the March issue of Urology Practice®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Tag: Drug Costs
With High Costs and Similar Benefits, Use of New Neurology Drugs Is Low
A number of new neurologic medications for diseases like multiple sclerosis (MS), Parkinson’s disease and migraine have received U.S. Food and Drug Administration (FDA) approval over the past decade. However, with most having higher out-of-pocket costs and benefits similar to existing, less expensive drugs, only a small percentage of people with neurologic conditions are being treated with these new drugs, according to a study funded by the American Academy of Neurology and published in the November 30, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Cost of Brand-Name Epilepsy Drugs Increased by 277% over Eight Years
The cost of brand-name drugs for epilepsy increased by 277% from 2010 to 2018, according to a study published in the June 15, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. The cost of generic drugs for epilepsy decreased by 42% over the same period.
MD Anderson Research Highlights: ASCO 2022 Special Edition
This special edition features upcoming oral presentations by MD Anderson researchers at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting focused on quality improvement, health services research, new treatments for skin cancers, and symptoms and survivorship advances. More information on ASCO content from MD Anderson can be found at MDAnderson.org/ASCO.
ACR Urges the FTC to Examine the Impact of Pharmacy Benefit Managers on Prescription Drug Costs
In comments submitted to the Federal Trade Commission (FTC), the American College of Rheumatology (ACR) urged the agency to address Pharmacy Benefit Manager (PBM) business practices that drive up costs and reduce access for the 54 million Americans living with rheumatic disease.
New study finds domestic reference pricing could lower Medicare spending on new drugs by 30%
Basing new drug launch prices on historical domestic data could limit manufacturers’ power to set extremely high launch prices and could reduce Medicare spending on new drugs by up to 30%, according to a new white paper released today by West Health and its Council for Informed Drug Spending Analysis (CIDSA).
Medicare Paid 50% More for Neurology Drugs Over 5 Years While Claims Rose Only 8%
A new study of Medicare payments has found that over a five-year period, the payments for medications prescribed to people with neurologic conditions like multiple sclerosis (MS), Parkinson’s disease and epilepsy increased by 50% while the number of claims for these prescription medications only rose by only 8%. The study is published in the March 10, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Why are US drug prices so high? What should a presidential policy to lower drug costs include?
The high price of prescription drugs is an important issue for voters, and in the past 50 years, Congress and the president have made little headway in restraining costs.
Eleven Provider and Patient Organizations Join the American College of Rheumatology to Oppose UnitedHealthcare Copay Accumulator Initiative
Eleven provider and patient organizations have joined the American College of Rheumatology (ACR) to petition UnitedHealthcare (UHC) to cancel plans to implement a proposed copay accumulator initiative that would require physicians to share details about their patients’ usage of copay assistance programs. The initiative would prevent funds from assistance programs from being applied towards patients’ annual deductible and out-of-pocket maximums. The groups warn that this would jeopardize patient access to medically necessary therapies by increasing the financial burden of care and lead to an increase in treatment abandonment.
Big drug costs for small patients with rare diseases, study finds
Only about one in every 170 children take them. But “orphan drugs” accounted for 1 in every 15 private insurance dollars spent on children’s health care in the United States in 2018, according to a new study. That’s up 65% from just five years before.